Stockreport

Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC [Yahoo! Finance]

Cardiff Oncology, Inc.  (CRDF) 
PDF onvansertib + FOLFIRI + bevacizumab arm produced a confirmed ORR of versus ~43% for standard-of-care, with deeper responses, median PFS not yet reached for onvansertib a [Read more]